Department of Pathology, Stanford University, Stanford, CA 94305, USA.
Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):E252-9. doi: 10.1073/pnas.1114817109. Epub 2012 Jan 10.
Defining the molecular genetic alterations underlying pancreatic cancer may provide unique therapeutic insight for this deadly disease. Toward this goal, we report here an integrative DNA microarray and sequencing-based analysis of pancreatic cancer genomes. Notable among the alterations newly identified, genomic deletions, mutations, and rearrangements recurrently targeted genes encoding components of the SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex, including all three putative DNA binding subunits (ARID1A, ARID1B, and PBRM1) and both enzymatic subunits (SMARCA2 and SMARCA4). Whereas alterations of each individual SWI/SNF subunit occurred at modest-frequency, as mutational "hills" in the genomic landscape, together they affected at least one-third of all pancreatic cancers, defining SWI/SNF as a major mutational "mountain." Consistent with a tumor-suppressive role, re-expression of SMARCA4 in SMARCA4-deficient pancreatic cancer cell lines reduced cell growth and promoted senescence, whereas its overexpression in a SWI/SNF-intact line had no such effect. In addition, expression profiling analyses revealed that SWI/SNF likely antagonizes Polycomb repressive complex 2, implicating this as one possible mechanism of tumor suppression. Our findings reveal SWI/SNF to be a central tumor suppressive complex in pancreatic cancer.
明确导致胰腺癌的分子遗传改变可能为这种致命疾病提供独特的治疗见解。为此,我们在此报告了一项胰腺癌细胞基因组的综合 DNA 微阵列和测序分析。在新鉴定的改变中值得注意的是,基因组缺失、突变和重排反复靶向编码 SWItch/Sucrose NonFermentable (SWI/SNF) 染色质重塑复合物的成分的基因,包括所有三个假定的 DNA 结合亚基(ARID1A、ARID1B 和 PBRM1)和两个酶亚基(SMARCA2 和 SMARCA4)。虽然每个 SWI/SNF 亚基的改变都以中等频率发生,作为基因组景观中的突变“山丘”,但它们共同影响了至少三分之一的胰腺癌,将 SWI/SNF 定义为主要的突变“山脉”。与肿瘤抑制作用一致,在 SMARCA4 缺陷的胰腺癌细胞系中重新表达 SMARCA4 降低了细胞生长并促进衰老,而在 SWI/SNF 完整的系中过表达则没有这种作用。此外,表达谱分析表明,SWI/SNF 可能拮抗 Polycomb 抑制复合物 2,暗示这是一种可能的肿瘤抑制机制。我们的发现表明 SWI/SNF 是胰腺癌中的一个重要肿瘤抑制复合物。